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Abstract
Objective—To compare neurodevelopmental outcomes in linear growth-restricted (LGR) infants 
born <29 weeks with and without weight gain out of proportion to linear growth
Study Design—We compared 2-year neurodevelopmental outcomes between infants with and 
without LGR and between LGR infants with and without weight gain out of proportion to linear 
growth. The outcomes were Bayley-III cognitive, motor, and language scores, cerebral palsy, 
Gross Motor Function Classification System (GMFCS) level ≥ 2, and neurodevelopmental 
impairment.
Result—1227 infants were analyzed. LGR infants were smaller and less mature at birth, had 
higher BMI, and had lower Bayley-III language scores (82.3 vs 85.0, p<0.05). Among infants with 
LGR, infants with high BMI had lower language scores compared to those with low-to-normal 
BMI (80.8 vs 83.3, p<0.05), and were more likely to have GMFCS level ≥ 2 and 
neurodevelopmental impairment.
Conclusion—Among infants with LGR, weight gain out of proportion to linear growth was 
associated with poorer neurodevelopmental outcomes.
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Introduction
The association of postnatal growth with neurodevelopmental outcomes in preterm infants is 
well established. Greater gains in weight, length, head circumference (HC), and body-mass 
index (BMI) during infancy have all been associated with improved neurodevelopmental 
scores measured during childhood.1, 2, 3, 4, 5 Greater attention has been paid to promoting 
weight gain and head growth in premature infants, although some data exist suggesting that 
linear growth is also important when considering long-term outcomes. For example, in very 
low birthweight infants, greater length z-score at discharge correlated with higher Bayley-III 
language score at 24 months6, and more rapid linear growth between term and 4 months’ 
corrected age was associated with lower odds of IQ < 85 at 18 months of age in preterm 
infants.7
In preterm infants, postnatal linear growth restriction (LGR), represented by a decline in 
length z-score from birth to discharge, is common.5, 6 Consequently, it is not uncommon for 
these infants to gain weight out of proportion to their gain in length, with a resulting increase 
in BMI. Although an increase in BMI between one week of age and term-equivalent age has 
been associated with improved neurodevelopmental outcomes in moderately preterm infants, 
it is unclear whether weight gain out of proportion to linear growth (i.e. high BMI), 
particularly in the setting of linear growth restriction, confers benefit for extremely preterm 
infants. The importance of following linear growth is that this measurement is a surrogate 
for lean body mass accrual and thus represents organ growth and differentiation.8 Thus, 
linear growth, rather than weight gain, may better represent brain growth and development 
in premature infants. The objective of this study was to compare neurodevelopmental 
outcomes among extremely preterm infants with and without LGR (measured from birth to 
discharge/120 days of age) and with high versus low-to-normal BMI (determined at 
discharge/120 days of age) in a population experiencing LGR. We hypothesized that, among 
infants with LGR, weight gain out of proportion to linear growth (i.e. high BMI) would not 
be associated with improved neurodevelopmental outcomes assessed at 2 years of age.
Methods
This is an observational, retrospective study of prospectively collected data as part of the 
National Institute for Child Health and Human Development’s Neonatal Research Network 
Generic Database (GDB) and Follow-Up studies. Infants 23 0/7 to 28 6/7 weeks gestation or 
with a birthweight of 401 to 1000 grams born 7/1/2012 to 6/30/2014 at participating NICHD 
Neonatal Research Network sites and who had neurodevelopmental assessment at 22–26 
months’ corrected age (CA) were considered for inclusion. Infants were excluded if they 
carried a diagnosis affecting linear growth (ex. skeletal dysplasia), had length z-score < −2 
(which may reflect an unknown inherited condition affecting linear growth) or HC z-score > 
2 at birth, or had missing growth or outcome data. All data collection for the birth 
hospitalization continued until infants reached “status”, defined as hospital discharge or 120 
days, whichever came first.
Length, weight and head circumference were measured according to the local practice in 
each neonatal intensive care unit (NICU); there is no standard practice or required method 
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for measuring length among NRN sites. Although the pattern of linear growth restriction has 
been previously described, there is no well-accepted definition. Standard deviation scores, or 
z-scores, have been used to describe patterns of growth in extremely preterm infants, and 
may be better suited to do so when compared with traditional growth percentiles.9 
Therefore, we chose to define LGR as being present when the length z-score at status was 
more than one point below the length z-score at birth, i.e.
LGR = Length z-score at status – length z-score at birth < −1
The Fenton growth chart10 served as the reference for growth percentiles and corresponding 
z-scores, which were determined using the bulk calculator provided at http://
www.ucalgary.ca/fenton/2013chart. BMI at status was used to determine high (≥ 75th 
percentile) versus low-to-normal (< 75th percentile) weight gain relative to linear growth. 
BMI percentile was determined using the Olsen11 (CA ≤ 41 weeks) and WHO (CA > 41 
weeks) BMI curves. Data collected included maternal/demographic characteristics, time to 
first feed and full feeds (120 mL/kg/day), duration of parenteral nutrition and postnatal 
steroid use. Additional data for in-hospital morbidities included rates of culture-positive 
sepsis (both early and late), necrotizing enterocolitis requiring surgery, grade 3–4 
intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), severe 
bronchopulmonary dysplasia (BPD, defined as receiving supplemental O2 or positive-
pressure ventilation for the first 28 days of life and receiving supplemental O2 ≥ 0.30 or 
positive-pressure ventilation at 36 weeks PMA or discharge if discharged before 36 weeks), 
retinopathy of prematurity (ROP) requiring surgery, and patent ductus arteriosus (PDA) 
requiring surgery. Standardized neurodevelopmental examinations were performed at 22–26 
months CA by certified examiners at each NRN center.12 Gross motor function was assessed 
with the Gross Motor Function Classification System (GMFCS) in all children. CP was 
defined as abnormal tone or reflexes in at least 1 extremity and abnormal control of 
movement or posture to a degree that interferes with age-appropriate activity. Children with 
CP were defined as having moderate-to-severe CP if they had a GMFCS level >2. The 
Bayley Scales of Infant Development, Third Edition13 were performed by trained, certified 
examiners.
The primary outcomes for this study were Bayley-III composite cognitive, motor, and 
language scores in LGR infants with high and low-normal BMI. Additional outcomes 
compared included the incidence of moderate/severe cerebral palsy, gross motor functional 
classification scale (GMFCS)14 level ≥ 2 and neurodevelopmental impairment (NDI), 
defined as Bayley-III composite cognitive score < 70, Bayley-III composite motor score < 
70, GMFCS level ≥ 2, bilateral blindness (< 20–200), or hearing impairment (permanent 
hearing loss that does not permit the child to understand directions of the examiner and 
communicate ± amplification with cochlear implants or hearing aids). These same outcomes 
were also compared between infants with and without LGR.
Bivariate analyses were used to compare demographic and clinical characteristics between 
LGR infants with excessive versus low-normal BMI, as well as between LGR and non-LGR 
infants using t-tests or Mann Whitney-U for continuous variables and exact tests for 
categorical variables. Generalized linear models and logistic regression were used to assess 
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the association of neurodevelopmental outcomes with LGR and with BMI among infants 
with LGR. Models were adjusted for maternal socioeconomic status (using maternal 
insurance status), infant gender, gestational age at birth, birth weight, small-for-gestational 
age, and center (model 1). A secondary analysis (model 2) also corrected for postnatal head 
growth, assessed as postnatal head-sparing, which has been previously defined as: HC z-
score at status – HC z-score at birth ≥ −1.9 All analyses were performed using SAS version 
9.4 with a p-value < 0.05 indicating statistical significance.
Results
Of the 2257 infants born 7/1/12 through 6/30/14, 595 (26%) died and an additional 435 
infants were excluded (Supplemental Figure). The most common reason for exclusion was 
missing growth or outcome data. From the remaining 1227 infants, 912 (74%) met the 
definition for LGR. For infants with LGR, 353 (39%) had a BMI ≥ 75th percentile at status.
Maternal and infant characteristics are compared between infants with and without LGR, as 
well as among LGR infants with high versus low-normal BMI as shown in Table 1. Maternal 
characteristics were similar between infants with and without LGR, as well as among LGR 
infants with high and low-normal BMI. Compared with infants without linear growth 
restriction, LGR infants had lower GA, BW, HC and BMI, but higher length, at birth and 
received more days of parenteral nutrition. Among infants with LGR, those with BMI at 
status ≥ 75th percentile were younger, had a higher BW and BMI at birth, and were less 
likely to be small for gestational age when compared with those with BMI < 75th percentile. 
LGR infants with a high BMI at status reached full feeds sooner and received fewer days of 
parenteral nutrition compared with LGR infants with a low-normal BMI.
Infant anthropometrics at status are shown in Table 2. Infants with and without LGR were of 
similar age at status, but LGR infants had lower weight, length and head circumference, and 
higher BMI compared to infants without LGR. Among infants with restricted linear growth, 
those with a high BMI at status were older, had a larger HC, and, as expected, had a 
significantly greater weight at status; the difference in mean weight at status was nearly 600 
grams.
The distributions of length (for all infants) and BMI curves (for LGR infants only) at birth 
and status are shown as density curves with histograms in Figure 1. As expected for infants 
with LGR, the distribution of length percentiles shifted leftward from birth to status, 
representing a negative change in z-score from birth to status, while the distribution in length 
percentiles for infants without LGR was preserved (Figure 1A). The distribution of BMI at 
birth for LGR infants with high versus low-normal BMI was relatively similar, and at status 
the difference noted in these distributions, shown in Figure 1B, represented weight gain out 
of proportion to linear growth (i.e. high vs low-normal BMI).
Results of bivariate analyses comparing in-hospital morbidities between groups are shown in 
Table 2. Compared to infants without LGR, those with LGR had higher rates of several 
morbidities including sepsis, grade 3–4 IVH and ROP requiring surgery. Among infants with 
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linear growth restriction, those with an elevated BMI at status were more likely to be 
diagnosed with BPD and receive postnatal steroids than those infants with low-normal BMI.
Bayley-III composite scores at 22–26 months are shown in Figure 2 for all groups. In 
unadjusted analyses, mean Bayley-III motor and language scores were significantly lower in 
infants with LGR versus those without LGR (86.3 vs 88.7 and 82.3 vs 85.0, respectively, 
p<0.05 for both comparisons). Among infants with LGR, mean Bayley-III language score 
was significantly lower in infants with a high BMI at status compared to those with a low-
normal BMI (80.8 vs 83.3, p=0.03). In the initial multivariable analysis, only the difference 
in Bayley-III language score between infants with and without LGR remained significantly 
different (adjusted mean difference −2.35, 95% CI −4.49 to −0.21, p=0.03) (Figure 2). 
Results of secondary outcomes are shown in Table 3. As noted, there were no significant 
differences in these outcomes between infants with and without LGR, and for LGR infants 
with high versus low-normal BMI in the initial multivariate analysis. However, after 
controlling for postnatal head growth, LGR infants with high BMI had lower observed 
Bayley-III language scores (adjusted mean difference −2.33, 95% CI −4.56 to −0.10, 
p=0.04) and higher odds of GMFCS level ≥ 2 (OR 1.69, 95% CI 1.05 to 2.72, p=0.03) and 
NDI (OR 1.50, 95% CI 1.02 to 2.20, p=0.04) compared with LGR infants with low-normal 
BMI. After addition of postnatal head growth to the multivariate model the difference in 
Bayley-III language scores between infants with and without LGR was no longer 
statistically significant (adjusted mean difference −2.07, 95% CI −4.25 to 0.11, p=0.06).
Discussion
In this study of premature infants born at <29 weeks’ gestation, we have shown that acquired 
LGR between birth and hospital discharge is common, present in three quarters of infants in 
the data set. LGR is associated with poorer language outcomes at 2 years’ corrected age. 
Among infants with LGR, additional weight gain alone does not ameliorate the 
neurodevelopmental deficits associated with linear growth restriction, and in fact may confer 
a disadvantage.
While the association between postnatal growth failure and poorer neurodevelopmental 
outcome in preterm infants has been well-established,1, 2, 4 growth failure has been largely 
described using weight gain and sometimes head circumference. As a result, greater 
attention is often paid to achieving weight gain, and perhaps head growth, with relatively 
little emphasis placed on achieving or maintaining linear growth. For example, the New 
York State Perinatal Quality Collaborative, working with 18 regional perinatal centers, has 
focused on reducing extrauterine growth restriction among infants < 31 weeks gestation 
since 2010.15 However, the collaborative focused on reducing the percent of infants 
discharged with weight < 10th percentile and improving head growth (measured as the 
difference in HC z-scores between birth and discharge), with no stated goal to improve 
linear growth.15
In a cohort of 62 very low birthweight infants, Ramel et al. reported a positive correlation 
between length z-score at NICU discharge and Bayley-III language score at 24 months’ CA, 
as well as a correlation between greater length z-score at 4 and 12 months’ CA and 
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improved cognitive scores at 24 months’ CA after controlling for weight and head 
circumference z-scores.6 Similarly, more rapid linear growth between term and 4 months’ 
CA was associated with improved neurodevelopmental scores at 18 months in infants born < 
33 weeks.1 Although these studies suggest that improved linear growth both before and after 
term-equivalent age is linked with neurodevelopment, to our knowledge ours is the first 
study to report on linear growth during hospitalization and neurodevelopmental outcomes in 
a large cohort comprised exclusively of extremely low gestational age newborns.
Whether greater weight gain relative to linear growth, reflected by an increase in BMI, 
confers neurodevelopmental benefit is still not clear. In infants born < 33 weeks, an increase 
in BMI from birth to term has been associated with better neurodevelopmental outcomes at 
18 months’ CA, and BMI gains later in infancy have been associated with lower odds of IQ 
< 85 later into childhood.1, 7 Moreover, the study by Belfort et al1 noted that the association 
between increasing BMI and improved neurodevelopmental outcomes was isolated to infants 
with birth weight < 1250 grams. In our study, LGR infants who experienced greater weight 
gain relative to linear growth, and thus an increase in BMI, did not experience improved 
neurodevelopmental outcomes at 2 years of age when compared with LGR infants with 
weight gain more proportional to linear growth (low-normal BMI). The exact reason for 
these conflicting results regarding BMI and neurodevelopment is not entirely clear, but may 
be due to the fact that our study focused specifically on outcomes in LGR infants. An 
increase in BMI, by definition, indicates a greater increase in weight relative to length. 
Anthropometric curves suggest an increase in BMI from birth to term in preterm infants is to 
be expected.11 The pattern of BMI increase associated with optimal outcomes however, such 
as weight gain with appropriate linear growth versus weight gain in the setting of linear 
growth restriction, is not well-established. In fact, weight gain out of proportion to linear 
growth may be undesirable for long-term health. On multivariable analysis, LGR infants 
with high BMI at status had lower Bayley-III language scores and were more likely to have 
GMFCS ≥ 2 and NDI when compared with LGR infants with low-normal BMI. 
Additionally, greater gains in BMI both before and after term have been associated with 
greater risk of obesity at 8 and 18 years of age in preterm infants.7 Identifying and 
promoting patterns of growth that optimize outcomes in preterm infants, particularly those 
born extremely premature, is critical to provide the highest level of care for these infants.
While the exact reasons for poor linear growth, as well as different patterns of weight gain in 
the setting of poor linear growth, remain unknown, it is reasonable to consider potential 
mechanisms. Certainly, nutritional mediators impact infant growth, including gains in 
length. Both longer time to reach full enteral feeds and greater caloric deficit during 
hospitalization have been associated with lower length z-score at discharge in VLBW 
infants.6 Nutritional interventions that promote early enteral feeding and target 
macronutrient recommendations have been successful in improving linear growth in preterm 
infants.16 Linear growth, a surrogate for lean body mass accrual, and thus organ growth, 
may better represent brain growth and development in premature infants. Specific nutrient 
and energy deficits can impact the growth and development of different brain regions, 
resulting in altered brain structure and function.17, 18, 19 More specifically, these nutrient and 
energy deficits, which occur commonly in premature infants, may result in regionalized 
effects on brain development. We speculate that critical windows of development likely exist 
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(before term, early infancy, and later infancy/childhood), which may help explain why 
certain growth parameters, such as linear growth, do not consistently correlate with 
neurodevelopmental outcomes across all previously investigated “windows”. Our database 
(GDB) does not have comprehensive nutritional information for these infants from which to 
draw conclusions about the role of nutrition in our findings.
In our population, LGR infants with elevated BMI at status were more likely to have BPD 
compared with LGR infants with low-normal BMI, and all LGR infants had a higher rate of 
culture-positive sepsis compared with infants without LGR. Thus, the role inflammation 
may play in poor linear growth should be considered. The accrual of lean body mass, 
measured indirectly by linear growth, is altered by systemic inflammation. A sepsis model in 
rats, mediated by TNF-α, results in decreased protein synthesis in skeletal muscle.20, 21 
Better outcomes in anthropometrics and bone growth have been observed in preterm infants 
with lower levels of inflammatory mediators.22, 23 While the incidence of BPD was 
significantly higher in LGR infants with high BMI, due to this hypothesis that the same 
underlying mechanism (i.e. systemic inflammation) may contribute to both LGR with high 
BMI and BPD, we have chosen not to additionally adjust models for BPD, as doing so 
would detract from the effect of interest. Moreover, though BPD has been associated with 
poorer neurodevelopmental outcomes in extremely preterm infants, conflicting data on the 
true influence of BPD on neurodevelopment exist, with some studies failing to demonstrate 
BPD as an independent influencer of neurodevelopmental impairment.25, 26, 27, 28
This study has several limitations. The definitions of both LGR and low-normal versus 
elevated BMI, although established a priori, were arbitrary. The definition of LGR does, 
however, parallel a similar cut-off defining postnatal head sparing (change in head 
circumference z-score ≥ −1 from birth to status) among growth-restricted premature infants 
that we have found to be associated with improved neurodevelopmental outcome.9 Length 
itself is inherently difficult to measure, and was not consistently measured using a length 
board, considered the most accurate method.24 Preliminary evaluation from the University of 
Rochester NICU has shown poor agreement between length measured serially by tape 
measure and length board, with only 62% of 97 paired measurements agreeing to within 1 
cm (unpublished data). However, the same evaluation showed no skew of tape measure 
measurements toward higher or lower values relative to length board determinations. Thus, 
tape measure lengths, while imprecise, were accurate (i.e., showed no systematic bias). As a 
result, while there may have been some misclassification of infants as having or lacking 
LGR at the borders of the current data, we would not expect any systematic 
misclassification. Another potential limitation exists with the choice of growth curves used 
to measure weight, length, HC and BMI. Slight differences do exist in the predicted 
percentiles for weight and length between the Fenton and Olsen curves, which may have 
introduced systematic bias. The Fenton curves, rather than Olsen, were chosen to calculate 
weight, length and HC z-scores because they were derived from a more comprehensive and 
diverse patient population and include infants born as young as 22 weeks gestation.10 
However, the Fenton anthropometric data do not include a weight-for-length comparison 
(such as BMI), and thus the Olsen BMI curves were used to calculate BMI percentiles for 
those infants ≤ 41 weeks CA. In this study, we expect any systematic bias to be slight, and 
thus believe the benefits of using the chosen growth curves outweigh this risk. Poor linear 
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growth in our population was associated with poor HC growth, which we and others have 
shown to predict poorer neurodevelopmental outcome.1, 2, 3, 4, 9 However, secondary 
analyses accounting for HC growth showed little difference in outcomes, suggesting that 
linear growth is an independent risk factor for poor neurodevelopmental outcome. Finally, 
the retrospective nature of the dataset and the limited nutritional data restrict both the ability 
to draw causal conclusions and the possibility of identifying potential mediators of LGR. On 
the other hand, conclusions drawn from this large dataset representing multiple centers is 
likely to be generalizable to other groups of similar infants.
Conclusion
Among extremely preterm infants with LGR, weight gain out of proportion to linear growth 
did not result in improved neurodevelopmental outcomes, and was associated with poorer 
performance on some measures. Improved linear growth during hospitalization is associated 
with improved language development; this finding deserves further exploration.
Supplementary Material
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Acknowledgements
The National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development (NICHD), and the National Center for Advancing Translational Sciences (NCATS) provided grant 
support for the Neonatal Research Network’s Generic Database and Follow-up Studies. NICHD staff provided input 
into the study design, conduct, analysis, and manuscript drafting; NCATS cooperative agreements provided 
infrastructure support to the NRN. The content is solely the responsibility of the authors and does not necessarily 
represent the official views of the National Institutes of Health.
Data collected at participating sites of the NICHD Neonatal Research Network (NRN) were transmitted to RTI 
International, the data coordinating center (DCC) for the network, which stored, managed and analyzed the data 
included in this study. On behalf of the NRN, Dr. Abhik Das (DCC Principal Investigator) and Sylvia Tan (DCC 
Statistician) had full access to all the data in the study and take responsibility for the integrity of the data and 
accuracy of the data analysis. The content is solely the responsibility of the authors and does not necessarily 
represent the official views of the National Institutes of Health.
We are indebted to our medical and nursing colleagues and the infants and their parents who agreed to take part in 
this study. The following investigators, in addition to those listed as authors, participated in this study:
NRN Steering Committee Chair: Michael S. Caplan, MD, University of Chicago, Pritzker School of Medicine.
Alpert Medical School of Brown University and Women & Infants Hospital of Rhode Island (UG1 HD27904) – 
Abbot R. Laptook, MD; Martin Keszler, MD; Betty R. Vohr, MD; Angelita M. Hensman, MS RNC-NIC; Elisa 
Vieira, RN BSN; Emilee Little, RN BSN; Barbara Alksninis, PNP; Mary Lenore Keszler, MD; Andrea M. Knoll; 
Theresa M. Leach, MEd CAES; Elisabeth C. McGowan, MD; Victoria E. Watson, MS CAS.
Case Western Reserve University, Rainbow Babies & Children’s Hospital (UG1 HD21364) – Michele C. Walsh, 
MD MS; Avroy A. Fanaroff, MD; Anna Maria Hibbs, MD MSCE; Nancy S. Newman, BA RN; Allison H. Payne, 
MD MS; Deanne E. Wilson-Costello, MD; Bonnie S. Siner, RN; Monika Bhola, MD; Gulgun Yalcinkaya, MD; 
Harriet G. Friedman, MA.
Children’s Mercy Hospital, University of Missouri Kansas City School of Medicine (UG1 HD68284) – William E. 
Truog, MD; Eugenia K. Pallotto, MD MSCE; Howard W. Kilbride MD; Cheri Gauldin, RN BS CCRC; Anne 
Holmes RN MSN MBA-HCM CCRC; Kathy Johnson RN, CCRC; Allison Knutson, BSN RNC-NIC.
Cincinnati Children’s Hospital Medical Center, University Hospital, and Good Samaritan Hospital (UG1 HD27853) 
– Brenda B. Poindexter, MD MS; Kurt Schibler, MD; Barbara Alexander, RN; Cathy Grisby, BSN CCRC; Teresa L. 
Meyers et al. Page 8
J Perinatol. Author manuscript; available in PMC 2019 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gratton, PA; Lenora Jackson, CRC; Kristin Kirker, CRC; Greg Muthig, BS; Stacey Tepe, BS; Kimberly Yolton, 
PhD.
Duke University School of Medicine, University Hospital, University of North Carolina, and Duke Regional 
Hospital (UG1 HD40492, UL1 TR1117, UL1 TR1111) – Ronald N. Goldberg, MD; C. Michael Cotten, MD MHS; 
Ricki F. Goldstein, MD; William F. Malcolm, MD; Patricia L. Ashley, MD PHD; Kimberley A. Fisher, PhD FNP-
BC IBCLC; Joanne Finkle, RN JD; Kathryn E. Gustafson, PhD; Matthew M. Laughon, MD MPH; Carl L. Bose, 
MD; Janice Bernhardt, MS RN; Gennie Bose, RN; Janice Wereszczak CPNP-AC/PC.
Emory University, Children’s Healthcare of Atlanta, Grady Memorial Hospital, and Emory University Hospital 
Midtown (UG1 HD27851) – David P. Carlton, MD; Ellen C. Hale, RN BS CCRC; Ira Adams-Chapman, MD; 
Yvonne Loggins, RN; Sheena L. Carter, PhD; Maureen Mulligan LaRossa, RN; Lynn C. Wineski, RN MS; Diane I. 
Bottcher, RN MSN; Colleen Mackie, BS RRT.
Eunice Kennedy Shriver National Institute of Child Health and Human Development – Rosemary D. Higgins, MD; 
Stephanie Wilson Archer, MA.
Indiana University, University Hospital, Methodist Hospital, Riley Hospital for Children, and Wishard Health 
Services (UG1 HD27856) – Gregory M. Sokol, MD; Brenda B. Poindexter, MD MS; Lu-Ann Papile, MD; Heidi M. 
Harmon, MD MS; Abbey C. Hines, PsyD; Leslie Dawn Wilson, BSN CCRC; Dianne E. Herron, RN CCRC; Susan 
Gunn, NNP CCRC; Lucy Smiley CCRC.
McGovern Medical School at the University of Texas Health Science Center at Houston, Children’s Memorial 
Hermann Hospital, and Memorial Hermann Southwest (UG1 HD87229, U10 HD21373) – Kathleen A. Kennedy, 
MD MPH; Jon E. Tyson, MD MPH; Elizabeth Allain, MS; Julie Arldt-McAlister, RN BSN; Allison G. Dempsey, 
PhD; Carmen Garcia, RN CCRP; Janice John, CPNP; Patrick M. Jones, MD; Layne M. Lillie, RN BSN; Karen 
Martin, RN; Sara C. Martin, RN; Georgia E. McDavid, RN; Shawna Rodgers, RN; Saba Siddiki, MD; Daniel 
Sperry, RN; Sharon L. Wright, MT (ASCP).
Nationwide Children’s Hospital and the Ohio State University Medical Center (UG1 HD68278) – Pablo J. Sánchez, 
MD; Leif D. Nelin, MD; Sudarshan R. Jadcherla, MD; Christine A. Fortney, PhD RN; Patricia Luzader, RN; Gail 
E. Besner; Nehal A. Parikh, MD.
RTI International (U10 HD36790) – Abhik Das PhD; Dennis Wallace, PhD; Jamie E. Newman, PhD MPH; Jeanette 
O’Donnell Auman, BS; Margaret Crawford, BS; Jenna Gabrio, BS CCRP; Marie G. Gantz, PhD; Carolyn M. Petrie 
Huitema, MS; Kristin M. Zaterka-Baxter, RN BSN.
Stanford University and Lucile Packard Children’s Hospital (UG1 HD27880, UL1 TR93) – Krisa P. Van Meurs, 
MD; David K. Stevenson, MD; Susan R. Hintz, MD MS Epi; M. Bethany Ball, BSc CCRC; Melinda S. Proud, 
RCP; Barbara Bentley, PsychD MSEd; Maria Elena DeAnda, PhD; Anne M. DeBattista, RN PNP PhD; Beth 
Earhart, PhD; Lynne C. Huffman, MD; Casey E. Krueger, PhD; Ryan Lucash, PhD; Hali E. Weiss, MD.
University of Alabama at Birmingham Health System and Children’s Hospital of Alabama (UG1 HD34216, M01 
RR32) – Waldemar A. Carlo, MD; Namasivayam Ambalavanan, MD; Myriam Peralta-Carcelen, MD MPH; Monica 
V. Collins, RN BSN MaEd; Shirley S. Cosby, RN BSN; Fred J. Biasini, PhD; Kristen C. Johnston, MSN CRNP; 
Cryshelle S. Patterson, PhD; Vivien A. Phillips, RN BSN; Sally Whitley, MA OTR-L FAOTA.
University of California - Los Angeles, Mattel Children’s Hospital, Santa Monica Hospital, Los Robles Hospital 
and Medical Center, and Olive View Medical Center (UG1 HD68270) – Uday Devaskar, MD; Meena Garg, MD; 
Isabell B. Purdy, PhD CPNP; Teresa Chanlaw, MPH; Rachel Geller, RN BSN.
University of Iowa and Mercy Medical Center (UG1 HD53109) – Tarah T. Colaizy, MD MPH; Jane E. Brumbaugh, 
MD; Dan L. Ellsbury, MD; Karen J. Johnson, RN BSN; Jacky R. Walker, RN; Donia B. Campbell, RNC-NIC; 
Diane L. Eastman, RN CPNP MA.
University of New Mexico Health Sciences Center (UG1 HD53089, UL1 TR41) – Kristi L. Watterberg, MD; Jean 
R. Lowe, PhD; Janell F. Fuller, MD; Robin K. Ohls, MD; Conra Backstrom Lacy, RN; Andrea F. Duncan, MD; Tara 
Dupont, MD; Elizabeth Kuan, RN BSN; Sandra Sundquist Beauman, MSN RNC-NIC.
University of Pennsylvania, Hospital of the University of Pennsylvania, Pennsylvania Hospital, and Children’s 
Hospital of Philadelphia (UG1 HD68244) – Barbara Schmidt, MD MSc; Haresh Kirpalani, MB MSc; Sara B. 
DeMauro, MD MSCE; Aasma S. Chaudhary, BS RRT; Soraya Abbasi, MD; Toni Mancini, RN BSN CCRC; Judy 
C. Bernbaum, MD; Marsha Gerdes, PhD; Hallam Hurt, MD; Noah Cook, MD; Dara M. Cucinotta, RN.
University of Rochester Medical Center, Golisano Children’s Hospital, and the University of Buffalo Women’s and 
Children’s Hospital of Buffalo (UG1 HD68263, UL1 TR42) – Satyan Lakshminrusimha, MD; Anne Marie 
Meyers et al. Page 9
J Perinatol. Author manuscript; available in PMC 2019 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Reynolds, MD MPH; Rosemary L. Jensen; Joan Merzbach, LMSW; Gary J. Myers, MD; Ashley Williams, MSEd; 
Kelley Yost, PhD; William Zorn, PhD; Karen Wynn, RN; Deanna Maffett, RN; Diane Prinzing; Julianne Hunn, BS; 
Stephanie Guilford, BS; Farooq Osman, MD; Mary Rowan, RN; Michael G. Sacilowski, BS; Holly I.M. Wadkins, 
MA; Melissa Bowman, MSN; Cait Fallone, MA; Kyle Binion, BS; Constance Orme; Ann Marie Scorsone, MS 
CCRC; Michelle Andrews-Hartley, MD.
University of Texas Southwestern Medical Center, Parkland Health & Hospital System, and Children’s Medical 
Center Dallas (UG1 HD40689) – Myra H. Wyckoff, MD; Pablo J. Sánchez, MD; Luc P. Brion, MD; Diana M. 
Vasil, MSN BSN; Lijun Chen, PhD RN; Roy J. Heyne, MD; Sally S. Adams, MS RN CPNP; Elizabeth Heyne, 
PsyD PA-C; Alicia Guzman; Lizette E. Lee, RN; Catherine Twell Boatman, MS CIMI.
Wayne State University, Hutzel Women’s Hospital and Children’s Hospital of Michigan (UG1 HD21385) – Seetha 
Shankaran MD; Athina Pappas, MD; Girija Natarajan, MD; Sanjay Chawla, MD; Monika Bajaj, MD; Melissa 
February, MD; Prashant Agarwal, MD; Kirsten Childs, RN BSN; Eunice Woldt, RN MSN; Rebecca Bara, RN 
BSN; Laura A. Goldston, MA; John Barks MD; Mary Christensen, RT; Stephanie Wiggins, MS; Diane White, RT.
References
1. Belfort MB, Rifas-Shiman SL, Sullivan T, Collins CT, McPhee AJ, Ryan P. et al. Infant growth 
before and after term: effects on neurodevelopment in preterm infants. Pediatrics 2011, 128(4): 
e899–906. [PubMed: 21949135] 
2. Ehrenkranz RA, Dusick AM, Vohr BR, Wright LL, Wrage LA, Poole WK. Growth in the neonatal 
intensive care unit influences neurodevelopmental and growth outcomes of extremely low birth 
weight infants. Pediatrics 2006, 117(4): 1253–1261. [PubMed: 16585322] 
3. Kan E, Roberts G, Anderson PJ, Doyle LW, Victorian Infant Collaborative Study G. The association 
of growth impairment with neurodevelopmental outcome at eight years of age in very preterm 
children. Early Hum Dev 2008, 84(6): 409–416. [PubMed: 18096332] 
4. Latal-Hajnal B, von Siebenthal K, Kovari H, Bucher HU, Largo RH. Postnatal growth in VLBW 
infants: significant association with neurodevelopmental outcome. J Pediatr 2003, 143(2): 163–170. 
[PubMed: 12970627] 
5. Modi M, Saluja S, Kler N, Batra A, Kaur A, Garg P. et al. Growth and neurodevelopmental outcome 
of VLBW infants at 1 year corrected age. Indian Pediatr 2013, 50(6): 573–577. [PubMed: 
23255692] 
6. Ramel SE, Demerath EW, Gray HL, Younge N, Boys C, Georgieff MK. The relationship of poor 
linear growth velocity with neonatal illness and two-year neurodevelopment in preterm infants. 
Neonatology 2012, 102(1): 19–24. [PubMed: 22441508] 
7. Belfort MB, Gillman MW, Buka SL, Casey PH, McCormick MC. Preterm infant linear growth and 
adiposity gain: trade-offs for later weight status and intelligence quotient. J Pediatr 2013, 163(6): 
1564–1569 e1562. [PubMed: 23910982] 
8. Forbes GB. Relation of lean body mass to height in children and adolescents. Pediatr Res 1972, 
6(1): 32–37. [PubMed: 5046969] 
9. Meyers JM, Bann CM, Stoll BJ, D’Angio CT, Bell EF, Duncan AF. et al. Neurodevelopmental 
outcomes in postnatal growth-restricted preterm infants with postnatal head-sparing. J Perinatol 
2016, 36(12): 1116–1121. [PubMed: 27629374] 
10. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for 
preterm infants. BMC Pediatr 2013, 13: 59. [PubMed: 23601190] 
11. Olsen IE, Lawson ML, Ferguson AN, Cantrell R, Grabich SC, Zemel BS. et al. BMI curves for 
preterm infants. Pediatrics 2015, 135(3): e572–581. [PubMed: 25687149] 
12. Newman JE, Bann CM, Vohr BR, Dusick AM, Higgins RD, Follow-Up Study Group of Eunice 
Kennedy Shriver National Institute of Child H. et al. Improving the Neonatal Research Network 
annual certification for neurologic examination of the 18–22 month child. J Pediatr 2012, 161(6): 
1041–1046. [PubMed: 22748517] 
13. Bayley N Bayley scales of infant and toddler development. San Antonio (TX): Harcourt 
Assessment; 2006.
14. Palisano RJ, Hanna SE, Rosenbaum PL, Russell DJ, Walter SD, Wood EP. et al. Validation of a 
model of gross motor function for children with cerebral palsy. Phys Ther 2000, 80(10): 974–985. 
[PubMed: 11002433] 
Meyers et al. Page 10
J Perinatol. Author manuscript; available in PMC 2019 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
15. Stevens TP, Shields E, Campbell D, Combs A, Horgan M, La Gamma EF. et al. Variation in Enteral 
Feeding Practices and Growth Outcomes among Very Premature Infants: A Report from the New 
York State Perinatal Quality Collaborative. Am J Perinatol 2016, 33(1): 9–19. [PubMed: 
26084749] 
16. Stefanescu BM, Gillam-Krakauer M, Stefanescu AR, Markham M, Kosinski JL. Very low birth 
weight infant care: adherence to a new nutrition protocol improves growth outcomes and reduces 
infectious risk. Early Hum Dev 2016, 94: 25–30. [PubMed: 26894665] 
17. Cooke RW. Are there critical periods for brain growth in children born preterm? Arch Dis Child 
Fetal Neonatal Ed 2006, 91(1): F17–20. [PubMed: 16223756] 
18. Fugelstad ARR, Georgieff M. The Role of Nutrition in Cognitive Development Handbook in 
Developmental Cognitive Neuroscience, 2nd edn. MIT Press: Cambridge, MA, 2008.
19. Georgieff MK. Nutrition and the developing brain: nutrient priorities and measurement. Am J Clin 
Nutr 2007, 85(2): 614S–620S. [PubMed: 17284765] 
20. Lang CH, Frost RA. Glucocorticoids and TNFalpha interact cooperatively to mediate sepsis-
induced leucine resistance in skeletal muscle. Mol Med 2006, 12(11–12): 291–299. [PubMed: 
17380194] 
21. Lang CH, Frost RA. Sepsis-induced suppression of skeletal muscle translation initiation mediated 
by tumor necrosis factor alpha. Metabolism 2007, 56(1): 49–57. [PubMed: 17161226] 
22. Ahmad I, Zaldivar F, Iwanaga K, Koeppel R, Grochow D, Nemet D. et al. Inflammatory and 
growth mediators in growing preterm infants. J Pediatr Endocrinol Metab 2007, 20(3): 387–396. 
[PubMed: 17451077] 
23. Eliakim A, Nemet D, Ahmad I, Zaldivar F, Koppel R, Grochow D. et al. Growth factors, 
inflammatory cytokines and postnatal bone strength in preterm infants. J Pediatr Endocrinol Metab 
2009, 22(8): 733–740. [PubMed: 19845124] 
24. Wood AJ, Raynes-Greenow CH, Carberry AE, Jeffery HE. Neonatal length inaccuracies in clinical 
practice and related percentile discrepancies detected by a simple length-board. J Paediatr Child 
Health 2013, 49(3): 199–203. [PubMed: 23432733] 
25. Karagianni P, Tsakalidis C, Kyriakidou M, Mitsiakos G, Chatziioanidis H, Porpodi M. et al. 
Neuromotor outcomes in infants with bronchopulmonary dysplasia. Pediatr Neurol 2011, 44(1): 
40–46. [PubMed: 21147386] 
26. Synnes A, Luu TM, Moddemann D, Church P, Lee D, Vincer M. et al. Determinants of 
developmental outcomes in a very preterm Canadian cohort. Arch Dis Child Fetal Neonatal Ed 
2017, 102(3): F235–F234. [PubMed: 27758929] 
27. Brumbaugh JE, Colaizy TT, Patel NM, Klein JM. The changing relationship between 
bronchopulmonary dysplasia and cognition in very preterm infants. Acta Paediatr 2018, 107(8): 
1339–1344. [PubMed: 29333635] 
28. Laughon M, O’Shea MT, Allred EN, Bose C, Kuban K, Van Marter LJ. et al. Chronic lung disease 
and developmental delay at 2 years of age in children born before 28 weeks’ gestation. Pediatrics 
2009, 124(2): 637–648. [PubMed: 19620203] 
Meyers et al. Page 11
J Perinatol. Author manuscript; available in PMC 2019 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Graphical depiction of length percentiles at birth and status for infants with (light gray bars, 
dotted line) and without (dark gray bars, solid line) LGR (A), and of BMI percentiles at birth 
and status for LGR infants with elevated (light gray bars, dotted line) versus low-normal 
(dark gray bars, solid line) BMI (B). The bars are constructed as histograms and the curves 
represent smoothed density curves. The third shade of gray noted is where the histogram 
bars overlap for each of the two groups. Note the leftward shift in length percentiles from 
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birth to status in infants with LGR (A), and the separation of BMI curves from birth to status 
in LGR infants (B) suggesting different patterns of weight gain relative to linear growth.
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Figure 2. 
Bar graph demonstrating the observed mean composite Bayley scores for infants without 
LGR (dark solid gray columns), with LGR (light solid gray columns), with LGR and 
elevated BMI (checkered gray columns) and with LGR and low-normal BMI (striped gray 
columns). The black bars represent the standard error. The # denotes a p-value < 0.05 
between groups on unadjusted analysis. After multivariate analyses, only the observed 
differences in language scores between infants with and without LGR (*, Model 1, p<0.05) 
and LGR infants with high versus low-normal BMI (^, Model 2, p<0.05) remained 
significant.
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